potential antiviral therapeutics for 2019 novel coronavirus CORD-Papers-2021-10-25 (Version 1)

Title: Potential antiviral therapeutics for 2019 Novel Coronavirus
Abstract: The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains - severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir / ritonavir, lopinavir / ritonavir combined with interferon-, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials.
Published: 2020
Journal: Zhonghua Jie He He Hu Xi Za Zhi
Author Name: Li, H
Author link: https://covid19-data.nist.gov/pid/rest/local/author/li_h
Author Name: Wang, Y M
Author link: https://covid19-data.nist.gov/pid/rest/local/author/wang_y_m
Author Name: Xu, J Y
Author link: https://covid19-data.nist.gov/pid/rest/local/author/xu_j_y
Author Name: Cao, B
Author link: https://covid19-data.nist.gov/pid/rest/local/author/cao_b
license: unk
license_url: [unknown license]
source_x: WHO
source_x_url: https://www.who.int/
who_covidence_id: #32023685
has_full_text: FALSE
G_ID: potential_antiviral_therapeutics_for_2019_novel_coronavirus
S2 ID: 211050109